Earnings results for Capricor Therapeutics (NASDAQ:CAPR)
Capricor Therapeutics, Inc. is expected* to report earnings on 11/12/2020 after market close. The report will be for the fiscal Quarter ending Sep 2020. The reported EPS for the same quarter last year was $-0.43.
Capricor Therapeutics last issued its earnings results on August 6th, 2020. The biotechnology company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.14. The business had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.21 million. Capricor Therapeutics has generated $0.00 earnings per share over the last year. Capricor Therapeutics has confirmed that its next quarterly earnings report will be published on Thursday, November 12th, 2020.
Analyst Opinion on Capricor Therapeutics (NASDAQ:CAPR)
2 Wall Street analysts have issued ratings and price targets for Capricor Therapeutics in the last 12 months. Their average twelve-month price target is $10.50, predicting that the stock has a possible upside of 123.88%. The high price target for CAPR is $12.00 and the low price target for CAPR is $9.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of “Buy.”
Capricor Therapeutics has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $10.50, Capricor Therapeutics has a forecasted upside of 123.9% from its current price of $4.69. Capricor Therapeutics has received no research coverage in the past 90 days.
Dividend Strength: Capricor Therapeutics (NASDAQ:CAPR)
Capricor Therapeutics does not currently pay a dividend. Capricor Therapeutics does not have a long track record of dividend growth.
Insiders buying/selling: Capricor Therapeutics (NASDAQ:CAPR)
In the past three months, Capricor Therapeutics insiders have not sold or bought any company stock. Only 8.60% of the stock of Capricor Therapeutics is held by insiders. Only 4.70% of the stock of Capricor Therapeutics is held by institutions.
Earnings and Valuation of Capricor Therapeutics (NASDAQ:CAPR
The P/E ratio of Capricor Therapeutics is -3.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Capricor Therapeutics is -3.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Capricor Therapeutics has a P/B Ratio of 3.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
More latest stories: here